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Epidemiologic evidence suggests that cancer incidence is associated with diabetes as well as
certaindiabetesriskfactorsanddiabetestreatments.Thisconsensusstatementofexpertsassem-
bled jointly by the American Diabetes Association and the American Cancer Society reviews the
state of science concerning 1) the association between diabetes and cancer incidence or prog-
nosis, 2) risk factors common to both diabetes and cancer, 3) possible biologic links between
diabetes and cancer risk, and 4) whether diabetes treatments inﬂuence risk of cancer or cancer
prognosis. In addition, key unanswered questions for future research are posed.
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D
iabetesandcancerarecommondis-
eases with tremendous impact on
health worldwide. Epidemiologic
evidence suggests that people with diabe-
tes are at signiﬁcantly higher risk for
many forms of cancer. Type 2 diabetes
and cancer share many risk factors, but
potential biologic links between the two
diseases are incompletely understood.
Moreover, evidence from observational
studies suggests that some medications
used to treat hyperglycemia are associated
witheitherincreasedorreducedriskofcan-
cer. Against this backdrop, the American
Diabetes Association and the American
Cancer Society convened a consensus de-
velopment conference in December 2009.
Followingaseriesofscientiﬁcpresentations
by experts in the ﬁeld, the writing group
independently developed this consensus
report to address the following questions:
1. Is there a meaningful association be-
tween diabetes and cancer incidence
or prognosis?
2. What risk factors are common to both
diabetes and cancer?
3. What are possible biologic links be-
tween diabetes and cancer risk?
4. Do diabetes treatments inﬂuence risk
of cancer or cancer prognosis?
For each area, the authors were asked to
address the current gaps in evidence and
potential research and epidemiologic
strategies for developing more deﬁnitive
evidence in the future. Table 1 includes a
summary of ﬁndings and recommenda-
tions.Recommendationsinthisreportare
solely the opinions of the authors and do
not represent ofﬁcial position of the
American Diabetes Association or the
American Cancer Society.
1. Is there a meaningful association
between diabetes and cancer
incidence or prognosis?
Both diabetes and cancer are prevalent
diseases whose incidence is increasing
globally. Worldwide, the prevalence of
cancer has been difﬁcult to establish be-
cause many areas do not have cancer reg-
istries, but in 2008 there were an
estimated 12.4 million new cancer cases
diagnosed. The most commonly diag-
nosed cancers are lung/bronchus, breast,
and colorectal, whereas the most com-
mon causes of cancer deaths are lung,
stomach, and liver cancer (1). In the U.S.,
the most commonly diagnosed cancers
are prostate, lung/bronchus, and colon/
rectum in men and breast, lung/
bronchus, and colon/rectum in women.
Oftheworldpopulationbetweentheages
of 20 and 79 years, an estimated 285 mil-
lionpeople,or6.6%,havediabetes(2).In
2007, diabetes prevalence in the U.S. was
10.7% of persons aged 20 years and older
(23.6 million individuals), with an esti-
mated 1.6 million new cases per year.
Type 2 diabetes is the most common
form, accounting for 95% of prevalent
cases (3). Worldwide, cancer is the 2nd
and diabetes is the 12th leading cause of
death (4). In the U.S., cancer is the 2nd
and diabetes is the 7th leading cause of
death; the latter is likely an underesti-
mate, since diabetes is underreported on
death certiﬁcates as both a cause and co-
morbid condition (3).
Cancer and diabetes are diagnosed
within the same individual more fre-
quently than would be expected by
chance, even after adjusting for age. Both
diseases are complex with multiple sub-
types. Diabetes is typically divided into
two major subtypes, type 1 and type 2
diabetes, along with less common types,
while cancer is typically classiﬁed by its
anatomic origin (of which there are over
50, e.g., lymphoma, leukemia, lung, and
breast cancer) and within which there
may be multiple subtypes (e.g., leuke-
mia). Further, the pathophysiologies un-
derlying both cancer and diabetes are
(with rare exceptions) incompletely
understood.
For more than 50 years, clinicians
have reported the occurrence of patients
with concurrent diabetes and cancer.
However, as early as 1959, Joslin et al. (5)
stated, “Studies of the association of dia-
betes and cancer have been conducted
over a period of years, but evidence of a
positive association remains inconclu-
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tween the two diseases was identiﬁed in
the 1960s in population-based studies.
More recently, the results of several stud-
ies have been combined for meta-analytic
study (6), indicating that some cancers
develop more commonly in patients with
diabetes (predominantly type 2), while
prostate cancer occurs less often in men
with diabetes. The relative risks imparted
by diabetes are greatest (about twofold or
higher) for cancers of the liver, pancreas,
and endometrium, and lesser (about 1.2–
1.5 fold) for cancers of the colon and rec-
tum, breast, and bladder. Other cancers
(e.g., lung) do not appear to be associated
withanincreasedriskindiabetes,andthe
evidence for others (e.g., kidney, non-
Hodgkinlymphoma)isinconclusive.Few
studies have explored links with type 1
diabetes.
Since insulin is produced by pancre-
atic -cells and then transported via the
portal vein to the liver, both the liver and
the pancreas are exposed to high concen-
trations of endogenously produced insu-
lin. Diabetes-related factors including
steatosis, nonalcoholic fatty liver disease,
and cirrhosis may also enhance suscepti-
bility to liver cancer. With regard to pan-
creaticcancer,interpretationofthecausal
nature of the association is complicated
by the fact that abnormal glucose metab-
olismmaybeaconsequenceofpancreatic
cancer (so-called “reverse causality”).
However, a positive association between
diabetes and pancreatic cancer risk has
been found when restricted to diabetes
that precedes the diagnosis of pancreatic
cancer by at least 5 years, so reverse cau-
sation does not likely account for the en-
tirety of the association.
Only for prostate cancer is diabetes
associated with a lower risk. This associ-
ation has been observed both before and
after the advent of screening with pros-
tate-speciﬁc antigen (PSA), so detection
bias due to differential PSA utilization
does not account for this ﬁnding. Some
metabolic factors associated with diabe-
tes, such as reduced testosterone levels,
may be involved (although circulating
testosterone levels have not been consis-
tently associated with prostate cancer in-
cidence). While obesity has not been
associated, and in some studies is even
inversely associated, with prostate cancer
incidence, obese men with prostate can-
cer have higher cancer mortality rates
than those of normal weight (7). In addi-
tion to metabolic factors such as hyperin-
sulinemia,obesitymaybeassociatedwith
clinicalfactors(suchasdelayeddiagnosis,
poorer treatment) that may underlie the
worsened prostate cancer prognosis.
Results of some, but not all, epidemi-
ological studies suggest that diabetes may
signiﬁcantlyincreasemortalityinpatients
with cancer (8). For example, in one
study, 5-year mortality rates were signiﬁ-
cantly higher (hazard ratio 1.39) in pa-
tients diagnosed with both breast cancer
and diabetes than in comparable breast
cancer patients without diabetes (9).
Since diabetes is associated with excess
age-adjusted mortality, whether the ap-
parent excess mortality associated with
diabetes in cancer patients is any greater
thantheexcessmortalityobservedamong
diabetic patients without cancer is un-
clear. Of note, higher pre-diagnosis C-
peptide levels (an indirect marker of
insulin resistance) have been associated
with a poorer disease-speciﬁc survival for
prostate cancer (7) and colorectal cancer
(10).
Unanswered questions
Diabetes has been consistently associated
with increased risk of several of the more
common cancers, but for many, espe-
cially the less common cancers, data are
limited or absent (6) and more research is
needed. Uncertainty is even greater for
theissueofdiabetesandcancerprognosis
or cancer-speciﬁc mortality. It remains
unclear whether the association between
diabetes and cancer is direct (e.g., due to
hyperglycemia), whether diabetes is a
markerofunderlyingbiologicfactorsthat
alter cancer risk (e.g., insulin resistance
and hyperinsulinemia), or whether the
cancer-diabetes association is indirect
and due to common risk factors such as
obesity.Whethercancerriskisinﬂuenced
by duration of diabetes is a critical and
complex issue and may be further com-
plicated by the multidrug therapy often
necessary for diabetes treatment (as dis-
cussed in question 4). What is also re-
quired is a better understanding of
whether diabetes inﬂuences cancer prog-
nosis above and beyond the prognosis
conferred by each disease state inde-
pendently.
To adequately address these ques-
tions,prospectivepopulation-basedstud-
ies with high-quality databases are
needed to compare incidence of speciﬁc
cancers between individuals with high
circulating insulin levels with or without
diabetesandnondiabeticindividualswith
normal insulin sensitivity (and therefore
low insulin levels). Examining other dia-
betes-related biomarkers (e.g., adiponec-
tin, hyperglycemia) is also critical.
Importantly, common confounders (such
as body weight and physical activity)
must also be more readily available and
assessed. Better characterization of as-
pects of diabetes (diabetes duration, ther-
apy, degree of glycemic control) in
relation to cancer risk is needed. In view
of the variable associations between dia-
betes and cancer risk at speciﬁc sites, the
authors discourage studies exploring
links between diabetes and risk of all can-
cers combined. For example, since lung
cancer does not appear to be meaning-
fully linked with diabetes, including this
common cancer in studies will dilute ob-
served associations, should they exist.
2. What risk factors are common to
both cancer and diabetes?
Potential risk factors (modiﬁable and
nonmodiﬁable) common to both cancer
and diabetes include aging, sex, obesity,
physical activity, diet, alcohol, and
smoking.
Nonmodiﬁable risk factors
Age. Although the incidence of some
cancers peaks in childhood or in young
adults, the incidence of most cancers in-
creases with age. In economically devel-
oped countries, 78% of all newly
diagnosed cancer occurs among individ-
uals aged 55 years and older (11). Diabe-
tes also becomes increasingly common
withage:Prevalenceis2.6%inU.S.adults
20–39 years of age, 10.8% in those
40–59 years of age, and increases to
23.8% in those 60 years of age or older
(3). In parallel with the obesity epidemic,
type 2 diabetes is becoming more fre-
quent among adolescents and young
adults(12,13),potentiallyaddingyearsof
additional risk from diabetes to the
population.
Sex. While certain cancers are sex-
speciﬁc (e.g., cervix, uterine, testicular,
prostate), or nearly so (breast), overall
cancer occurs more frequently in men.
Men have slightly higher age-adjusted
risk of diabetes than women (3).
Race/ethnicity. The age-standardized
incidence of cancer and diabetes varies
signiﬁcantly among different popula-
tions. Factors that may contribute to this
variabilityincludedifferencesintheprev-
alence of major risk factors, genetic fac-
tors, medical practices such as screening,
and completeness of reporting. In the
U.S.,AfricanAmericansaremorelikelyto
develop and die from cancer than other
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Americans are non-Hispanic whites, with
Hispanics, Native Americans, and Asian
Americans/Paciﬁc Islanders having lower
cancer incidence and mortality (14). As
with the worldwide situation, the U.S.
race/ethnic variability in cancer incidence
is attributed, at least in part, to socioeco-
nomic and other disparities, but biologi-
calfactors,suchaslevelsofhormonesthat
vary by race (15), may also play a role.
In the U.S., type 2 diabetes and its
complications disproportionately affect a
number of speciﬁc populations, includ-
ingAfricanAmericans,NativeAmericans,
Hispanics, and Asian Americans/Paciﬁc
Islanders compared with non-Hispanic
whites (3). While incompletely under-
stood, genetic, socioeconomic, lifestyle,
and other environmental factors are
thought to contribute to these disparities.
Modiﬁable risk factors
Overweight, obesity, and weight
change. Overweight(BMI25and30
kg/m
2) or obese (BMI 30 kg/m
2) indi-
viduals have a higher risk for many types
of cancer compared with individuals
whose BMI is considered within the nor-
mal range (18.5 to 25 kg/m
2) (16,17).
The cancers most consistently associated
withoverweightandobesityarebreast(in
postmenopausal women), colon/rectum,
endometrium,pancreas,adenocarcinoma
of the esophagus, kidney, gallbladder,
and liver. Obesity may also increase risk
of mortality from some cancers, such as
prostate (7). A growing body of evidence
suggests that weight gain is associated
with an increased risk of some cancers,
breast cancer in particular (17). Increases
in body weight during adulthood largely
reﬂect increases in adipose tissue rather
than lean mass, so total body fat may be
a better measure of the risk for cancer
than BMI.
Studies over decades have consis-
tentlyshownastrongassociationbetween
obesity and both insulin resistance and
type 2 diabetes incidence (18), with risk
ofdiabetesandearlierageatonsetdirectly
linked to obesity severity (19). For type 2
diabetes (20) as well as certain cancers
(e.g., colon) (21), some studies suggest
that waist circumference, waist-to-hip ra-
tio, or direct measures of visceral adipos-
ity are associated with risk independently
of BMI.
The case for a causal relationship be-
tween obesity and disease is strengthened
by evidence that weight loss lowers dis-
ease risk. In the case of diabetes, numer-
ous studies have shown that weight loss
decreases diabetes incidence and restores
euglycemia in a signiﬁcant fraction of
individuals with type 2 diabetes. In the
randomized, prospective, multicenter
Diabetes Prevention Program trial, an in-
tensive lifestyle intervention of diet (tar-
geting 5–7% weight loss) and physical
activity was associated with a 58% reduc-
tion in diabetes incidence in high-risk in-
dividuals(22),andweightlossaccounted
for most of the effect (23). In addition,
weight loss may also limit the risk of de-
veloping gestational diabetes (24).
The association between weight loss
and subsequent cancer risk is less clear.
Most evidence has been derived from
breast cancer studies, where weak or null
associations were observed. Since the
weight loss deﬁnition and the referent
groupsdifferedacrossstudies,thesestud-
ies are difﬁcult to compare. Weight loss
categories tend to have small numbers,
and many women who do lose weight do
not maintain their weight loss beyond 1
year.IntheNurses’HealthStudy,astatis-
tically signiﬁcant inverse association be-
tween adult weight loss and post-
menopausalbreastcancerwasfoundonly
when the weight loss had been main-
tained for two survey cycles, or 4 years
(25). Observational studies of weight loss
and cancer risk require extremely large
sample sizes with long-term follow-up
and careful monitoring of weight change.
One concern of all observational studies
of weight loss and subsequent cancer risk
is that weight loss may be a sign of undi-
agnosed cancer. As a practical matter, a
randomized clinical trial to study the ef-
fect of weight loss on cancer risk is un-
likely to be feasible; such a study would
have to be very large and would likely be
stopped early due to a protective effect on
diabetes and heart disease before enough
cancer end points would accumulate.
The signiﬁcant amount of weight lost
with bariatric surgery may also provide
clarity to this issue. However, a recent
summary (26) noted the limited evidence
oftheeffectsofbariatricsurgeryoncancer
incidence. Among the studies published
to date, three found that obese women
who underwent bariatric surgery were at
lowerriskofcancer(relativerisksranging
from 0.58 to 0.62) compared with un-
treated obese women. The inverse associ-
ations appeared to be due in large part to
a protective effect on breast and endome-
trial cancer. In the two studies that in-
cluded men, no association between
bariatric surgery and cancer risk was
observed.
Bariatric surgery is a very effective
treatmentfortype2diabetes,withameta-
analysis showing that type 2 diabetes re-
solved in 78% and resolved or improved
in 87% of patients after bariatric surgery
(27). In contrast to the known effects of
bariatric surgery on treating diabetes, the
therapy’s role in preventing diabetes
wouldseemlikelybuthasnotbeenestab-
lished through prospective trials.
Diet. A majority of studies (despite dif-
ferent study designs and differing study
populations) suggest that diets low in red
and processed meats and higher in vege-
tables, fruits, and whole grains are associ-
ated with a lower risk of many types of
cancer (17,28,29). Diets that are low in
red and processed meat but high in
monounsaturated fatty acids, fruits, vege-
tables, whole grain cereals, and dietary ﬁ-
ber may protect against type 2 diabetes,
possibly through improving insulin sen-
sitivity (30,31). Low-carbohydrate diets
(which often include greater consump-
tion of red meats and fat) have also been
associated with weight loss and improve-
ments in insulin sensitivity and glycemic
control.However,randomizedcontrolled
trial evidence of dietary interventions and
diabetes prevention only exists for low-
fat, low-calorie, plus/minus high-ﬁber di-
ets (22,32).
Several studies suggest that diets high
in foods with a high glycemic index or
load are associated with an increased risk
of type 2 diabetes (28,33). However, evi-
dence of their associations with cancer
risk is mixed (28,34,35). Regardless, to
the extent that energy-dense and sugary
foods contribute to overweight and obe-
sity, the American Cancer Society, the
World Cancer Research Fund, and the
American Institute for Cancer Research
recommend limiting consumption of
these foods (17,29).
Physical activity. Evidence from obser-
vational epidemiologic studies consis-
tently shows that higher levels of physical
activity are associated with a lower risk of
colon, postmenopausal breast, and endo-
metrial cancer (17,36,37). Physical activ-
ity may also help prevent other cancers,
including lung and aggressive prostate
cancer, but a clear link has not been es-
tablished. Some evidence also suggests
that physical activity postdiagnosis may
improvecancersurvivalforsomecancers,
including breast (38) and colorectal (39).
A protective role for increased physi-
cal activity in diabetes metabolism and
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from observational and randomized trials
suggest that 30 min of moderate-
intensity exercise, such as walking, at
least 5 days per week substantially re-
duces (25–36%) the risk of developing
type 2 diabetes (40). Analyses of the ef-
fectsofdifferentcomponentsoftheinten-
sive lifestyle intervention in the Diabetes
Prevention Program suggested that those
who did not reach weight loss goals still
signiﬁcantlyreducedtheirriskofdiabetes
if they reached the exercise goals, al-
though weight loss was the only compo-
nent independently associated with
diabetes prevention in multivariate anal-
yses (23).
Tobacco smoking. It is estimated that
worldwide,tobaccosmokingaccountsfor
71% of all trachea, bronchus, and lung
cancer deaths (41). Other cancers
strongly associated with smoking are lar-
ynx, upper digestive, bladder, kidney,
pancreas, leukemia, liver, stomach, and
uterine cervix. Studies suggest that smok-
ing is also an independent risk factor for
the development of diabetes (42,43). In
addition, because of the effect of smoking
on increasing risk of cardiovascular dis-
ease, retinopathy, and other complica-
tions of diabetes, smoking has an adverse
effect on diabetes-related health out-
comes (44).
Alcohol. Alcoholic beverage consump-
tion,eveninmoderateamounts,increases
theriskofmanytypesofcancerincluding
those of the oral cavity, pharynx, larynx,
esophagus, liver, colon/rectum, and fe-
male breast (45). While excess alcohol
consumption is also a risk factor for dia-
betes, moderate alcohol consumption has
been associated with reduced diabetes in-
cidence in both men and women (46,47).
Unanswered questions
A critical question is whether the associa-
tions between diabetes and risk of certain
cancers is largely due to shared risk fac-
tors (obesity, poor diet, physical inactiv-
ity, and aging), or whether diabetes itself,
and the speciﬁc metabolic derangements
typical of diabetes (e.g., hyperglycemia,
insulin resistance, hyperinsulinemia), in-
crease the risk for some types of cancer.
While it is clear that lower levels of adi-
posity, healthy diets, and regular physical
activity are associated with reduced risk
for type 2 diabetes and for several com-
mon types of cancer, these factors are
generally interrelated, making the
contribution of each factor difﬁcult to as-
sess. More research is needed to under-
stand the role of speciﬁc components of
healthy lifestyles independent of others
(e.g., diet quality independent of body
weight). In addition, further study of
those who are of normal body weight but
have hyperinsulinemia or are sedentary,
and of those who are obese but have nor-
mal metabolic parameters, is necessary to
better understand the relationship be-
tween diabetes and cancer risk. Little is
knownabouthowmodiﬁablelifestylefac-
tors inﬂuence prognosis in cancer pa-
tients.Howgeneticvariantsthatinﬂuence
diverse aspects of diabetes (e.g., insulin
resistance, -cell depletion) inﬂuence
cancer risk may provide insights into the
nature of the diabetes-cancer relation-
ship. Addressing these questions will re-
quire large, long-term observational
studies, with their inherent limitations.
Although not powered for cancer out-
comes, long-term trials such as the Look
AHEAD trial of the effects of weight loss
on cardiovascular outcomes in patients
with diabetes (48), and follow-up of co-
horts in lifestyle studies such as the Dia-
betes Prevention Program, may provide
furtherevidencefortheimpactoflifestyle
improvements on cancer incidence.
3. What are possible biologic links
between diabetes and cancer risk?
Carcinogenesis is a complex process.
Normal cells must undergo multiple ge-
netic “hits” before the full neoplastic
phenotype of growth, invasion, and me-
tastasis occurs. This process of malignant
transformation can be divided into multi-
ple steps: initiation (irreversible ﬁrst step
toward cancer), promotion (stimulation
of the growth of initiated cells), and
progression (development of a more ag-
gressive phenotype of promoted cells).
Factors that affect one or more steps of
this pathway could be associated with
cancer incidence or mortality. Diabetes
may inﬂuence the neoplastic process by
several mechanisms, including hyperin-
sulinemia (either endogenous due to in-
sulin resistance or exogenous due to
administered insulin or insulin secreto-
gogues), hyperglycemia, or chronic
inﬂammation.
The insulin/IGF axis
Insulin and insulin-like growth factor
(IGF) receptors form a complex network
ofcellsurfacereceptors;homodimersand
heterodimers have been described, and
all function to mediate insulin and IGF
responses (49). Most cancer cells express
insulinandIGF-Ireceptors;theAisoform
of the insulin receptor is commonly ex-
pressed.TheAreceptorisoformcanstim-
ulate insulin-mediated mitogenesis, even
in cells deﬁcient in IGF-I receptors (50).
In addition to its metabolic functions, the
insulin receptor is also capable of stimu-
lating cancer cell proliferation and metas-
tasis. Because most glucose uptake in
cancer cells is constitutively high and in-
dependent of insulin binding to its recep-
tor (51), the effects of insulin receptor
activation on neoplastic cells may relate
moretocellsurvivalandmitogenesisthan
to enhanced glucose uptake.
Multiple signaling pathways are acti-
vated after insulin receptors or IGF-I re-
ceptors interact with their ligands. By
phosphorylating adaptor proteins, most
notably the insulin receptor substrate
(IRS) family, the initial kinase event is
linkedtodownstreamsignalingpathways
(52). Once activated, these signaling
pathways may stimulate multiple cancer
phenotypes including proliferation, pro-
tection from apoptotic stimuli, invasion,
and metastasis, potentially enhancing
promotionandprogressionofmanytypes
of cancer cells. It is also clear that insulin/
IGF may stimulate normal cells that are
involved in cancer progression. For ex-
ample, hyperglycemia allows IGF-I to
stimulate vascular smooth muscle cell
proliferation and migration (53). While
this process has been linked to the patho-
physiology of atherosclerosis, abnormal
vasculature growth is also a hallmark of
cancer.
Apart from direct effects of insulin on
cancer cells, it is possible that hyperinsu-
linemia could promote carcinogenesis in-
directly through its effects on IGF-I (54).
Insulin reduces the hepatic production of
IGF binding protein (IGFBP)-1 (55,56)
and possibly IGFBP-2 (57) with resultant
increases in the levels of circulating free,
bioactive IGF-I. IGF-I has more potent
mitogenic and anti-apoptotic activities
than insulin (58) and could act as a
growth stimulus in preneoplastic and
neoplastic cells that express insulin,
IGF-I, and hybrid receptors (49). Human
tumors commonly over-express these re-
ceptors, and many cancer cell lines have
been shown to be responsive to the mito-
genic action of physiological concentra-
tions of IGF-I.
As has been found in other cancers,
insulinreceptorsarefrequentlyexpressed
by breast cancer cells (59). Compared
with the ligand (i.e., insulin), higher lev-
els of insulin receptor have been associ-
ated with favorable breast cancer
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these ﬁndings may seem to be contradic-
tory, they are consistent with other hor-
mone-dependent pathways in breast
cancer. Elevated serum levels of estradiol
are weakly associated with increased
breast cancer risk (62), while expression
of estrogen receptor (ER)- is a favorable
prognostic factor (63). Just like ER, insu-
lin receptor may be a marker of breast
cancer cell differentiation and identify
cells with a potentially less aggressive
phenotype. On the other hand, a recent
larger study (64) concluded that high in-
sulin receptor levels are related to adverse
prognosis; further research is needed.
Moreover, the relationship between se-
rum levels of insulin and regulation of in-
sulin receptor levels in neoplastic tissues
has never been established. Since growth
factors may downregulate the expression
of their cognate receptors, it is possible
thattumorswithlowinsulinreceptorlev-
els are the most insulin-stimulated. Thus,
there are biologically plausible models
and correlative human clinical studies
suggesting that insulin acting through in-
sulin receptors might affect breast cancer
risk and progression.
Effect of hyperinsulinemia on other
hormones
Increased circulating insulin has a num-
ber of indirect effects including a reduc-
tion in the hepatic synthesis and blood
levels of sex hormone binding globulin,
leading to increases in bioavailable estro-
gen in both men and women and in-
creased levels of bioavailable testosterone
in women but not in men (65). Androgen
synthesis in the ovaries and possibly the
adrenalsisincreasedbyhyperinsulinemia
in premenopausal women. Elevated en-
dogenous sex steroid levels are associated
with a higher risk of postmenopausal
breast, endometrial, and possibly other
cancers.
Hyperglycemia and cancer
In considering the complexity of interac-
tions between diabetes, diabetes treat-
ments, and cancer, it is important to not
overlook glucose as a potentially relevant
mediator. The recent resurgence of inter-
est in the Warburg hypothesis and cancer
energetics (66) emphasizes the depen-
dence of many cancers on glycolysis for
energy, creating a high requirement for
glucose (or even “glucose addiction”),
since ATP generation by glycolysis re-
quires far more glucose than oxidative
phosphorylation. Indeed, this forms the
basis for FDG-PET imaging of cancers,
which detects tissues with high rates of
glucose uptake. The possibility that un-
treated hyperglycemia facilitates neo-
plastic proliferation therefore deserves
consideration. Direct data concerning
dose-response characteristics of cancers
toglucosearesparse,butitisrelevantthat
most cancers have highly effective up-
regulated, insulin-independent glucose
uptake mechanisms (67) and therefore
may not derive a further growth advan-
tage from hyperglycemia.
In vivo models showing reduced tu-
mor growth in the setting of type 1 diabe-
tes (68) suggest that hyperglycemia does
notleadtoincreasedneoplasticgrowth,at
least in the setting of insulin deﬁciency.
Studies relating hyperglycemia to cancer
do not necessarily indicate that glucose
mediates the relationship; rather, hyper-
glycemia may serve as a surrogate for a
causative factor such as hyperinsulin-
emia. Given the molecular heterogeneity
of cancers, one cannot at this point ex-
clude the possibility that there exists a
subsetoftumorsforwhichhyperglycemia
confersagrowthadvantageandappropri-
ate therapy for diabetes therefore limits
tumorgrowth,buttheaggregatedatasug-
gest that insulin receptor activation may
be a more important variable than hyper-
glycemia in determining tumor growth.
Inﬂammatory cytokines, diabetes,
and cancer risk
In addition to the direct effects of insulin,
type 2 diabetes and/or the related obesity
might enhance other pathways resulting
in malignant progression. As recently re-
viewed, adipose tissue is an active endo-
crine organ producing free fatty acids,
interleukin-6 (IL-6), monocyte chemoat-
tractant protein, plasminogen activator
inhibitor-1 (PAI-1), adiponectin, leptin,
and tumor necrosis factor- (69). Each of
these factors might play an etiologic role
in regulating malignant transformation or
cancer progression. In some cases, the
role for these molecules is well known.
Forexample,theplasminogensystemhas
been linked to cancer with expression of
PAI-1 linked to poor outcome in breast
cancer (70). Activation of signal trans-
ducer and activator of transcription pro-
tein (STAT) signaling, via cytokines such
as IL-6, is known to enhance cancer cell
proliferation,survival,andinvasionwhile
also suppressing host anti-tumor immu-
nity (71).
Similarly, animal studies of energy
balance support epidemiologic results re-
lating obesity with cancer mortality. Cer-
tain experimental cancers tend to behave
more aggressively when animals overeat
andlessaggressivelywhenanimalsareca-
lorically restricted (72–74). These studies
provide evidence that diet-induced
changes in IL-6 and/or insulin may medi-
ate the effect of diet on neoplasia and in-
dicate that differences between tumors
with respect to speciﬁc signaling path-
ways determine the extent to which diet
inﬂuences tumor behavior (75).
Major unanswered questions
As previously outlined, there is a growing
body of epidemiologic evidence support-
ing a link between diabetes and the inci-
dence and/or prognosis of some cancers.
Itisrecognizedtheassociationmaynotbe
causal; diabetes and cancer may be asso-
ciatedsimplybecausetheysharecommon
predisposing risk factors such as obesity.
However, a number of plausible biologic
mechanisms have been described that
may account for this link, including ef-
fectsofhyperglycemia,hyperinsulinemia,
and inﬂammation on cancer etiology and
progression. Mechanisms by which these
factors interact with cancer risk require
further study. Another important area for
investigationconcernstheissueofinsulin
resistance in type 2 diabetes in cells of
non-classic insulin target organs, such as
the breast, colon, or prostate. The as-
sumption that in the setting of insulin
resistance of classic insulin target or-
gans (liver, muscle, adipose tissue) at
least a subset of cancers remain insulin-
sensitive, or that insulin insensitivity to
metabolic pathways does not extend to
resistance to growth-promoting proper-
ties, needs to be more closely examined.
How common is this? And what are the
dose-response characteristics of insulin
stimulation of such cancers?
Research is ongoing to provide a
clearer understanding of these possible
links, and this information may be rele-
vant for prevention and optimal patient
management. Most of the supporting ev-
idence on biologic mechanisms comes
from in vivo and in vitro studies. Since
multiple prediagnostic biospecimens are
rarely available on cohorts large enough
forstudiesofcancer,manyepidemiologic
studies are only able to evaluate a single
time point when measuring levels of in-
sulin, glucose, or other analytes. The risk
of long-term exposure to high levels of
insulin is relatively underexplored and
has direct relevance to the cancer risk as-
sociatedwithdiabetesdurationanduseof
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the large studies have only fasting levels;
postprandial (area under the curve) insu-
lin levels have not been adequately
examined.
4. Do diabetes treatments inﬂuence
cancer risk or cancer prognosis?
Improved glucose control remains one of
thecentralgoalsofeffectivediabetesman-
agement, which strives to minimize mor-
bidity and mortality by reducing the risk
of diabetes-associated complications.
Several factors are considered by clini-
cians and patients when selecting phar-
macologic diabetes therapies. These
includethetypeofdiabetesbeingtreated,
the glucose-lowering potential of a given
agent, known acute and chronic adverse
effects of treatment (such as weight gain,
hypoglycemia, ﬂuid retention, gastroin-
testinal intolerance), treatment costs, and
patient comorbidities and characteris-
tics. Only recently has the issue of can-
cer risk with diabetes treatments been
considered.
Individuals with type 1 diabetes rep-
resent 5% of the diabetes population
worldwide. The autoimmune destruction
of the pancreatic -cells results in the loss
of insulin production and the need for
immediate and lifelong insulin therapy.
In contrast, type 2 diabetes is much more
common and accounts for 95% of the
diabetes population. Type 2 diabetes is
generally associated with overweight and
obesity(inanestimated80%ofcases)and
commonly advances from a pre-diabetic
state characterized by insulin resistance
(hyperinsulinemia)tofrankdiabeteswith
sustained insulin resistance accompanied
by a progressive reduction in insulin se-
cretion. The resulting relative insulin de-
ﬁciency gives rise to both fasting and
postmeal hyperglycemia. Ongoing loss of
insulin secretory capacity, along with a
diminished incretin effect and several
other pathophysiologic defects (76),
makes the hyperglycemia of type 2 diabe-
tes progressive. This results in increasing
use of pharmacologic agents over time
and the eventual need for insulin therapy
in approximately half of all patients (77).
The selection of the most appropriate
pharmacologic agent(s) for each patient
involves clinical decision-making process
that includes an ongoing risk/beneﬁt
analysis (78).
Metformin
The biguanide metformin is the most
commonly used therapy in patients with
type 2 diabetes, often prescribed as initial
or combination therapy (79). While the
mechanism of action of metformin in di-
abetes is only partially understood, met-
formin treatment generally reduces levels
of both circulating glucose and insulin in
patients with insulin resistance and hy-
perinsulinemia. The primary mode of ac-
tion is through reduced hepatic glucose
output (80).
In laboratory studies, metformin has
been shown to inhibit cell proliferation,
reduce colony formation, and cause par-
tial cell cycle arrest in cancer cell lines
(81–83). These studies suggest that met-
formin-induced activation of AMP-
activatedproteinkinase(AMPK)intumor
cells may lead to growth inhibition, at
least in part by inhibiting protein synthe-
sis (84). Interestingly, in vivo studies
show that metformin has less antineo-
plastic activity in mice on a control diet
than it does in mice on a high-energy
diet associated with hyperinsulinemia
and accelerated tumor growth (74).
This suggests that the insulin-lowering
actionofmetforminmaycontributetoits
anti-neoplastic activity, and that it may
have less impact on cancers in less hyper-
insulinemic patients. Other in vitro stud-
iessuggestthatmetforminmayselectively
kill cancer stem cells and enhance effec-
tiveness of breast cancer treatment regi-
mens (85–87). Metformin has also been
showntoreducemammarytumorgrowth
in rodent models (88).
Resultsofagrowingnumberofobser-
vational human studies suggest that treat-
ment with metformin (relative to other
glucose-lowering therapies) is associated
with reduced risk of cancer (89–93) or
cancer mortality (94). However, these
studies have generally been limited in
theirabilitytoassessassociationwithspe-
ciﬁc cancer types. Confounding by indi-
cation may limit the interpretation of
resultsfromobservationalstudies,asmet-
formin is most typically prescribed to
those with short duration of diabetes and
without contraindicating factors (ad-
vanced age, liver, or kidney disease) that
also might impact risk of some cancers.
Additional observational data suggest
that metformin might improve cancer
prognosis. Metformin treatment was as-
sociated with higher pathologic complete
response among early-stage breast cancer
patients receiving neoadjuvant therapy
(95).Thepotentialeffectofmetforminon
breast cancer cell proliferation (as mea-
sured by Ki67 index) is currently being
evaluated in a clinical trial with a small
number of subjects (96), and other trials
of metformin therapy in patients with
breast cancer are planned.
Thiazolidinediones
Thiazolidinediones (TZDs) are insulin-
sensitizing peroxisome proliferator–
activated receptor (PPAR) agonists that
do not increase insulin secretion directly
or cause hypoglycemia when used alone.
Two drugs in this class, pioglitazone and
rosiglitazone, are currently available. Un-
like metformin, TZDs may be used in pa-
tients with renal insufﬁciency, although
ﬂuid retention is a potential adverse ef-
fect. TZDs are contraindicated in selected
patients, most notably those with liver
disease or with active untreated or unsta-
ble congestive heart failure.
In vitro studies indicate that PPAR
agonists have several anti-cancer activi-
ties, such as inhibiting growth and induc-
ingapoptosisandcelldifferentiation(97),
and PPAR is currently considered a po-
tential target for both chemoprevention
and cancer therapy based on other pre-
clinical studies (98,99). However, since
recent in vitro studies indicate that the
effects of PPAR agonists on cell growth
are often independent of the presence of
PPAR (100–102), the clinical relevance
of ﬁndings of in vitro studies is unclear.
Rodent studies also indicate that PPAR
agonists can potentiate tumorigenesis,
andtheyhavebeenconsideredbysometo
be multi-species, multi-sex carcinogens
(103). Therefore, it is possible that TZDs
may increase, decrease, or have a neutral
effect on the risk of cancer or cancer pro-
gression in humans.
Deﬁnitive human data on cancer risk
associated with TZDs are not available.
Three epidemiologic studies conducted
among patients with diabetes focused on
all cancers combined or only on a limited
number of cancer sites, and results were
inconsistent (104–106). Results of a re-
cent meta-analysis of clinical trials of
rosiglitazone showed no statistically sig-
niﬁcant increase or decrease in the risk of
canceratallsitescombinedoratthemore
common sites, although the numbers of
cancer cases at these speciﬁc sites were
small (107). The epidemiologic studies
andthemeta-analysisoftrialswereableto
examine only short-term exposure,
largely due to the relatively recent intro-
duction of these medications and the
shorter duration of many clinical efﬁcacy
trials.
Only a few clinical trials of TZDs for
cancer treatment have been conducted,
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(108). Other clinical trials are in progress
(109) or are planned (99).
Insulin secretagogues
Secretagogues, including sulfonylureas
and the rapid-acting glinides, stimulate
-cells to release insulin by binding to
speciﬁc cell receptors, resulting in -cell
depolarization and release of insulin
stores. Sulfonylureas (e.g., glyburide,
glipizide, glimepiride) have been used to
treat type 2 diabetes for more than 50
years. While this class of agents is one of
the more effective in lowering A1C, these
drugscancausehypoglycemiaandweight
gain. A small number of observational
studies found a higher risk of cancer or
cancer death among individuals with di-
abetes treated with sulfonylureas com-
pared with those treated with metformin
or other diabetes medications (90–
92,110). However, most of these studies
had very few cancer cases among users of
sulfonylureas, and therefore power was
limited to examine associations with spe-
ciﬁc cancer sites (91,111). Studies regard-
ingdose,duration,recency,andpersistence
of use are limited.
While it is possible that the associ-
ation of sulfonylureas and cancer risk
is genuine, it is difﬁcult to determine
whether the ﬁndings reﬂect excess cancer
among users of the secretagogues or re-
duced risk in those using comparator
drugs, which often include metformin
therapy. Furthermore, if the association
were to be conﬁrmed, it remains to be
determined if the mechanism involves di-
rect actions of the agents on transformed
cells or cells at risk for carcinogenesis, as
compared with indirect effects mediated
by increased insulin levels. There are no
published data that support an associa-
tion between the glinide secretagogues
and cancer risk, perhaps because they are
newer and use of these agents is less
common.
Incretin-based therapies
Two recently developed classes of drugs
either enhance or mimic the effect of gut-
derived incretin hormones that improve
glucose-dependent insulin secretion,
suppress postprandial glucagon levels,
and delay gastric emptying. The ﬁrst of
the incretin-based therapies introduced,
exenatide, has 50% homology with the
incretinhormoneglucagon-likepeptide1
(GLP-1), while the more recently ap-
proved liraglutide is an analog of human
GLP-1. Both compounds bind to the
GLP-1 receptor to exert agonist activity.
The oral dipeptidyl peptidase-4 (DPP-4)
inhibitors inhibit the action of the ubiq-
uitous enzyme that rapidly degrades
many peptides including endogenous
GLP-1.
Liraglutide increased risk of medul-
lary thyroid cancer in rats and mice in
preclinical tests and was associated with
slight increases in serum calcitonin in hu-
man trials (U.S. Food and Drug Adminis-
tration). Exenatide, liraglutide, and
DPP-4 inhibitors increased -cell prolif-
erationinanimalstudies,andinonesmall
study of a transgenic rodent model, the
DPP-4 inhibitor sitagliptin was demon-
strated to increase pancreatic ductal hy-
perplasia (112). No impact of incretin-
based agents on human cancer incidence
has been reported, likely due to the fact
that these newer drugs have not been
used in sufﬁcient numbers of patients or
for long enough periods of time to fully
assess any possible effects on cancer risk.
Insulin and insulin analogs
Insulin is required for all patients with
type 1 diabetes. It is also necessary for
manypatientswithtype2diabetestotreat
hyperglycemia,inpartduetotheprogres-
sive loss of -cell function over time. Be-
tween40–80%ofindividualswithtype2
diabetes will ultimately be considered for
insulin therapy in an effort to achieve gly-
cemic targets (77). Several formulations
of insulin exist: short-acting human reg-
ular insulin, intermediate-acting human
NPH insulin, and both rapid- and long-
acting analogs of human insulin. Subcu-
taneous injection of insulin results in
signiﬁcantly higher levels of circulating
insulin in the systemic circulation than
endogenous insulin secretion, thereby
possibly amplifying links between hyper-
insulinemia and cancer risk.
Recently,aseriesofwidelypublicized
epidemiologicanalysesexaminedapossi-
ble association between insulin use
and/or use of the long-acting insulin ana-
log glargine (91,110,113,114) and an in-
crease in risk of cancer. As noted below,
insulin glargine may have a disparate im-
pact on cancer risk through its binding to
IGF-1 receptors. The potential strengths
and weaknesses of these studies have
been broadly debated and well detailed
(115–117). For example, one concern is
thatinsulinismorecommonlyprescribed
in patients with longer duration of type 2
diabetes and is used more often in those
with one or more comorbid conditions
that preclude use of comparator medica-
tions. Rarely have these or other potential
confounders (body mass, actual insulin
dose, degree of glucose control, glucose
variability, other patient characteristics)
been fully accounted for in the study de-
signs or analyses.
Randomized clinical trial data from
an open-label 5-year trial of insulin
glargine versus NPH insulin did not ﬁnd
evidence of excess cancer risk (all sites
combined) in the insulin glargine arm
(118), although among the 1,000 sub-
jects randomized, there was a very small
number of cancer end points (57 cancer
cases in the glargine arm and 62 cases in
the NPH arm). The ongoing randomized
ORIGIN trial (glargine versus placebo in
patients with impaired fasting glucose or
newly diagnosed type 2 diabetes) is much
larger(12,000patientsrandomizedand
followed for 6–7 years) (119). Impor-
tantly, this trial was powered for cardio-
vascular outcomes and may still not
provide deﬁnitive evidence regarding
cancer incidence, especially for speciﬁc
cancers.
Possible mechanisms for the link
between exogenous insulin, insulin
analogs, and cancer
Potential mechanisms by which adminis-
tration of insulin or insulin analogs might
inﬂuence neoplastic disease include both
direct and indirect actions. Direct actions
have received the most attention and in-
volve interactions of the administered li-
gands (or their metabolites) with cancer
cells, partially transformed cells, or cells
at risk for transformation. Indirect mech-
anisms have been less well studied but
would involve interactions of signaling
molecules whose levels (e.g., glucagon,
adiponectin,orIGFBPs)oractivityarein-
ﬂuencedbyadministeredinsulinonthese
target cells.
With respect to direct actions, one
must consider not only the afﬁnity of the
administeredagentsforthevariousrecep-
tors involved, but also pharmacokinetic
aspects. Substantial prior research has
emphasized differences between human
insulinandanaloginsulinswithrespectto
binding afﬁnity to the IGF-I receptor, in-
cluding evidence that insulin glargine has
much higher afﬁnity, and higher mito-
genic potency, than human insulin or
other analogs (120–122). The afﬁnity of
particularanaloginsulinsfortheIGF-Ire-
ceptor is an important issue, in view of
evidence that knockdown of the IGF-1
receptor, but not the insulin receptor,
abolished proliferation of malignant cell
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However, the implicit assumption that an
insulin or analog that retains speciﬁcity
for the insulin receptor over the IGF-I re-
ceptor is unlikely to have important mi-
togeniceffectsoreffectsonneoplasiamay
besimplisticinthelightofrecentresearch
results(64,123)thatshowthattheinsulin
receptor is present on neoplastic cells and
mayitselfinﬂuenceneoplasticbehaviorin
certain contexts.
Other pharmacokinetic issues must
alsobeconsidered.Itisnotclearifthereis
a biologic difference between exposure of
neoplastic cells to ﬂuctuating levels of en-
dogenous insulin seen under normal
physiologicconditions,ascomparedwith
the levels of endogenous insulin in
obesity, type 2 diabetes, and/or after ad-
ministration of exogenous human or syn-
thetic insulins. Classic subcutaneous
therapy with subcutaneous human insu-
lin involves transient exposures to very
high insulin levels, while subcutaneous
administration of some synthetic insulins
results (by design) in longer-term expo-
sure to higher insulin concentrations. As
such, simple pharmacokinetics may not
fully explain observed changes in the be-
havior of neoplastic tissues. It also is crit-
icaltorecognizethatcancercellsintype2
diabetic patients may be exposed to ab-
normally high levels of endogenous insu-
lin for many years prior to administration
of exogenous insulin.
Unanswered questions
There are several important limitations in
human studies of diabetes treatment and
cancer risk that require careful consider-
ation.First,moststudieshavehadlimited
power to detect modest associations, par-
ticularly for site-speciﬁc cancers. Con-
ducting studies with all sites combined
might attenuate or even mask important
associations with only speciﬁc cancer
sites. Another limitation of observational
studies is that most diabetic patients are
treatedwithoneormoreanti-hyperglyce-
mic medications. Indeed, the progressive
nature of type 2 diabetes, requiring
changes in pharmacotherapy over time,
adds complexity to studies of a long-term
outcomesuchascancerincidence.There-
fore, it is extremely difﬁcult to assess the
independent association of a speciﬁc
medication on cancer risk relative to no
medication. For example, if some medi-
cationsincreaserisk,whileotherdecrease
or have no effect on risk, different com-
parator drugs will likely lead to different
associations and may explain some of the
observed inconsistencies across studies.
Because speciﬁc anti-hyperglycemic
medications are associated with cancer
risk factors, confounding by unmeasured
or incompletely measured risk factors
may at least in part explain the previously
reported drug-cancer associations. Few
studies examined risk associated with
dose, duration, or recency of medication
use, which might inform the biologic
plausibility of observed associations.
Many agents that affect carcinogenesis
have long latencies or require a minimum
exposure level, and risk associated with
some agents may return to baseline after
the exposure has been terminated for a
period of time. Some diabetes medica-
tionshaveonlyrecentlycomeonthemar-
ket (e.g., TZDs, insulin analogs, incretin-
based therapies). Therefore, studies of
these agents will only assess cancer risk
associated with relatively short-term use.
Itisunlikelythattheeffectofdiabetes
therapies on cancer risk and progres-
sion—particularly at speciﬁc cancer
sites—will be fully addressed with ran-
domized controlled clinical trials, due to
bothcost-andfollow-uptimelimitations.
Such trials would also be confounded by
the natural crossover and treatment esca-
lation required to appropriately treat pro-
gressive hyperglycemia. Given these
limitations, multiple well-conducted and
appropriately designed prospective ob-
servational studies are needed. Results of
in vitro and preclinical studies should in-
form design considerations for observa-
tional studies but by themselves cannot
be considered conclusive.
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Table 1—Summary and recommendations
● Diabetes (primarily type 2) is associated with increased risk for some cancers (liver, pancreas, endometrium, colon and rectum, breast,
bladder). Diabetes is associated with reduced risk of prostate cancer. For some other cancer sites there appears to be no association or the
evidence is inconclusive.
● The association between diabetes and some cancers may partly be due to shared risk factors between the two diseases, such as aging,
obesity, diet, and physical inactivity.
● Possible mechanisms for a direct link between diabetes and cancer include hyperinsulinemia, hyperglycemia, and inﬂammation.
● Healthful diets, physical activity, and weight management reduce risk and improve outcomes of type 2 diabetes and some forms of cancer
and should be promoted for all.
● Patients with diabetes should be strongly encouraged by their health care professionals to undergo appropriate cancer screenings as
recommended for all people in their age and sex.
● The evidence for speciﬁc drugs affecting cancer risk is limited, and observed associations may have been confounded by indications for
speciﬁc drugs, effects on other cancer risk factors such as body weight and hyperinsulinemia, and the complex progressive nature of
hyperglycemia and pharmacotherapy in type 2 diabetes.
● Although still limited, early evidence suggests that metformin is associated with a lower risk of cancer and that exogenous insulin is
associated with an increased cancer risk. Further research is needed to clarify these issues and evaluate if insulin glargine is more strongly
associated with cancer risk compared with other insulins.
● Cancer risk should not be a major factor in choosing between available diabetes therapies for the average patient. For selected patients with
very high risk for cancer occurrence (or for recurrence of speciﬁc cancer types), these issues may require more careful consideration.
● Many research questions remain, as described in the article.
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